WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareBiotechnology
Best Biotech Stocks to Buy Now (2024)
Top biotech stocks in 2024 ranked by overall Zen Score. See the best biotech stocks to buy now, according to analyst forecasts for the biotechnology industry.

Industry: Biotechnology
Ticker
Company
Performance Score
Market Cap
Revenue
EBITDA
Earnings
EPS
Revenue Growth Y/Y
Revenue Growth 5Y
Earnings Growth Y/Y
Earnings Growth 5Y
Earnings Date
INCY
INCYTE CORP
$13.60B$3.70B$919.43M$597.60M$2.678.87%14.45%74.51%38.71%
HRMY
HARMONY BIOSCIENCES HOLDINGS INC
$1.84B$582.02M$221.51M$128.85M$2.1732.93%N/A-29.32%N/A
ARCT
ARCTURUS THERAPEUTICS HOLDINGS INC
$999.99M$296.24M$94.16M$99.33M$3.76475.22%N/AN/AN/A2024-03-07
VYGR
VOYAGER THERAPEUTICS INC
$359.88M$158.40M$55.06M$52.31M$1.33124.58%67.66%N/AN/A2024-02-28
AMLX
AMYLYX PHARMACEUTICALS INC
$1.20B$380.79M$55.39M$49.27M$0.731,612.94%N/AN/AN/A
CPRX
CATALYST PHARMACEUTICALS INC
$1.50B$348.39M$105.42M$62.04M$0.5981.69%N/A-9.23%N/A2024-02-28
UTHR
UNITED THERAPEUTICS CORP
$10.68B$2.33B$1.39B$984.80M$21.0420.20%7.41%31.66%9.22%
ZYME
ZYMEWORKS INC
$835.82M$461.58M$236.66M$205.24M$3.241,445.86%44.15%N/A130.31%
GMAB
GENMAB A
$19.27B$2.40BN/A$633.48M$0.9716.77%39.38%-17.74%21.77%
EXEL
EXELIXIS INC
$6.53B$1.83B$312.21M$207.77M$0.6513.60%16.47%14.04%-22.47%
HALO
HALOZYME THERAPEUTICS INC
$5.14B$829.25M$451.95M$281.59M$2.1325.62%40.43%43.92%N/A
RPRX
ROYALTY PHARMA PLC
$18.54B$2.35B$1.32B$1.13B$2.545.24%5.58%2,440.00%N/A
REVB
REVELATION BIOSCIENCES INC
$587.75k$0.00$900.11k$875.06k$59.40N/AN/A-97.15%N/A2024-03-28
CORT
CORCEPT THERAPEUTICS INC
$2.32B$482.38M$109.00M$105.50M$1.0220.04%13.93%7.37%9.43%
MEIP
MEI PHARMA INC
$28.72M$72.65M$21.69M$19.84M$2.9716.10%83.24%N/AN/A
MGNX
MACROGENICS INC
$1.13B$121.13M$64.93M$49.82M$0.8130.26%-9.24%N/AN/A2024-03-13
BMRN
BIOMARIN PHARMACEUTICAL INC
$17.19B$2.31B$268.62M$147.02M$0.7715.05%9.08%71.11%N/A2024-04-24
ROIV
ROIVANT SCIENCES LTD
$9.35B$123.24M$4.58B$4.47B$5.56185.76%N/AN/AN/A
SYRS
SYROS PHARMACEUTICALS INC
$152.95M$8.80M-$97.30M-$104.96M$0.86-62.47%50.03%N/AN/A2024-02-29
FBIO
FORTRESS BIOTECH INC
$15.56M$80.97M-$51.99M-$82.32M$4.314.32%N/AN/AN/A2024-03-28
OCUP
OCUPHIRE PHARMA INC
$56.59M$57.21M$29.08M$28.75M$1.46N/AN/AN/AN/A2024-03-28
VNDA
VANDA PHARMACEUTICALS INC
$256.04M$192.64M$9.35M$2.51M$0.04-24.27%-0.05%-63.64%-39.66%
OBIO
ORCHESTRA BIOMED HOLDINGS INC
$215.89M$3.60M-$48.35M-$44.04M$7.35N/AN/A179.47%N/A
PLX
PROTALIX BIOTHERAPEUTICS INC
$105.78M$63.63M$15.89M$10.62M$0.1433.75%17.68%N/AN/A2024-02-26
CLGN
COLLPLANT BIOTECHNOLOGIES LTD
$65.05M$10.72M-$5.42M-$6.73M-$0.591,845.19%64.31%N/AN/A2024-03-27
CRSP
CRISPR THERAPEUTICS AG
$6.74B$371.21M-$130.89M-$153.61M-$1.9430,885.48%160.00%N/AN/A
NRBO
NEUROBO PHARMACEUTICALS INC
$25.71M$0.00-$9.63M-$11.83M$38.80N/AN/AN/AN/A2024-03-28
LIFE
ATYR PHARMA INC
$111.85M$10.74M-$40.12M-$43.15M-$0.97N/AN/AN/AN/A2024-03-07
REGN
REGENERON PHARMACEUTICALS INC
$107.70B$13.12B$4.69B$3.95B$37.057.76%20.58%-8.54%10.34%
NVO
NOVO NORDISK A S
$556.76B$33.81B$16.66B$12.18B$2.7234.95%14.94%56.54%17.71%
MRKR
MARKER THERAPEUTICS INC
$35.02M$9.06M-$8.33M-$9.29M-$1.10126.81%113.15%N/AN/A2024-03-20
DNTH
DIANTHUS THERAPEUTICS INC
$362.15M$924.00k-$65.92M-$67.40M-$17.70-21.23%N/AN/AN/A2024-03-21
SPRO
SPERO THERAPEUTICS INC
$80.03M$77.70M$1.06M-$1.61M$0.39781.74%88.47%N/A-64.99%2024-03-28
TECH
BIO-TECHNE CORP
$11.26B$1.14B$372.91M$224.16M$1.412.25%10.93%-15.57%17.11%
ZLAB
ZAI LAB LTD
$1.97B$263.49M-$283.10M-$300.96M-$3.1034.02%N/AN/AN/A2024-02-28
QURE
UNIQURE NV
$302.17M$111.90M-$190.47M-$228.47M-$4.8082.16%55.62%N/AN/A2024-02-26
AGIO
AGIOS PHARMACEUTICALS INC
$1.85B$26.82M-$334.75M-$352.09M-$6.3388.36%-22.25%N/AN/A
APRE
APREA THERAPEUTICS INC
$27.05M$569.16k-$14.44M-$13.29M$12.34N/AN/AN/AN/A2024-03-28
PRTA
PROTHENA CORP PUBLIC LTD CO
$1.46B$91.37M-$152.07M-$147.03M-$2.7669.50%148.98%N/AN/A
IGMS
IGM BIOSCIENCES INC
$755.62M$1.85M-$224.51M-$238.30M-$4.97165.57%N/AN/AN/A2024-03-28
RNA
AVIDITY BIOSCIENCES INC
$1.04B$10.14M-$198.23M-$202.25M-$3.0022.02%N/AN/AN/A2024-02-26
VRNA
VERONA PHARMA PLC
$1.32B$458.00k-$47.85M-$50.69M-$0.56N/AN/AN/AN/A2024-02-29
JANX
JANUX THERAPEUTICS INC
$724.38M$8.47M-$60.77M-$62.60M-$1.4814.68%N/AN/AN/A2024-03-10
KNSA
KINIKSA PHARMACEUTICALS LTD
$1.41B$248.75M-$6.75M-$6.69M-$0.1140.50%N/AN/AN/A2024-02-28
LPCN
LIPOCINE INC
$20.25M-$3.07M-$16.28M-$16.30M-$2.96N/AN/AN/AN/A2024-03-08
AXSM
AXSOME THERAPEUTICS INC
$3.74B$270.60M-$223.54M-$239.24M-$5.27440.80%N/AN/AN/A
DBVT
DBV TECHNOLOGIES SA
$161.57M$5.55M-$91.84M-$100.78M-$0.55-38.88%N/AN/AN/A2024-03-06
EDIT
EDITAS MEDICINE INC
$637.87M$24.61M-$202.79M-$195.08M-$2.70-4.03%-3.55%N/AN/A2024-02-28
INM
INMED PHARMACEUTICALS INC
$2.47M$5.49M-$5.75M-$6.35M-$1.27239.77%N/AN/AN/A
SEER
SEER INC
$98.29M$16.83M-$85.28M-$91.00M-$1.4420.60%N/AN/AN/A2024-02-29
MORF
MORPHIC HOLDING INC
$1.77B$521.00k-$150.62M-$152.10M-$3.59-99.26%-31.11%N/AN/A2024-04-23
SPRY
ARS PHARMACEUTICALS INC
$801.58M$1.35M-$20.84M-$19.96M$0.39-80.27%N/A-26.42%N/A2024-03-21
FULC
FULCRUM THERAPEUTICS INC
$593.50M$2.62M-$96.46M-$98.71M-$1.65-75.56%N/AN/AN/A2024-02-27
ANIX
ANIXA BIOSCIENCES INC
$113.80M$210.00k-$9.77M-$9.81M-$0.32N/A-28.36%N/AN/A2024-03-08
MIRM
MIRUM PHARMACEUTICALS INC
$1.30B$144.73M-$140.24M-$164.19M-$4.29176.75%N/AN/AN/A2024-02-28
IMMP
IMMUTEP LTD
$265.96M$3.29M-$25.24M-$25.25M-$0.28-23.58%-8.02%N/AN/A
XCUR
EXICURE INC
$5.28M$23.79M$5.04M$3.07M$1.68584.21%38.63%N/A-72.96%2024-03-25
PGEN
PRECIGEN INC
$363.42M$6.76M-$77.27M-$85.02M-$0.37-76.55%-48.29%N/AN/A2024-03-04
VTGN
VISTAGEN THERAPEUTICS INC
$133.50M$1.04M-$31.51M-$32.07M-$3.43N/AN/AN/AN/A
IDYA
IDEAYA BIOSCIENCES INC
$3.42B$23.39M-$108.95M-$112.96M-$1.96-54.08%N/AN/AN/A
CRMD
CORMEDIX INC
$179.78M$29.70k-$39.68M-$39.79M-$0.86-67.75%-43.05%N/AN/A2024-03-28
LXRX
LEXICON PHARMACEUTICALS INC
$622.11M$531.00k-$148.56M-$157.86M-$0.77324.80%-63.37%N/AN/A2024-02-29
DNLI
DENALI THERAPEUTICS INC
$2.34B$340.81M-$105.80M-$124.43M-$0.93207.89%150.09%N/AN/A2024-02-26
ABIO
ARCA BIOPHARMA INC
$23.64M$0.00-$5.23M-$5.34M-$0.37N/AN/AN/AN/A2024-04-22
BOLT
BOLT BIOTHERAPEUTICS INC
$46.32M$7.20M-$66.54M-$71.29M-$1.8949.15%N/AN/AN/A2024-03-27
CRNX
CRINETICS PHARMACEUTICALS INC
$2.46B$4.72M-$197.77M-$199.42M-$3.63-7.52%16.77%N/AN/A2024-02-28
VRTX
VERTEX PHARMACEUTICALS INC
$111.10B$9.87B$4.61B$3.62B$14.0510.51%26.49%8.33%11.26%
PPBT
PURPLE BIOTECH LTD
$13.79M$0.00$21.44M$21.06MN/AN/AN/AN/AN/A
ARVN
ARVINAS INC
$2.59B$167.20M-$278.20M-$295.40M-$5.5231.97%65.53%N/AN/A
VERV
VERVE THERAPEUTICS INC
$857.47M$7.63M-$180.97M-$192.80M-$3.08720.88%N/AN/AN/A2024-03-11
MRVI
MARAVAI LIFESCIENCES HOLDINGS INC
$2.10B$419.52M$109.46M$24.56M$0.18-53.73%N/A-90.11%N/A
ONTX
ONCONOVA THERAPEUTICS INC
$14.49M$226.00k-$20.17M-$20.18M-$0.970.00%-29.65%N/AN/A2024-03-14
CBAY
CYMABAY THERAPEUTICS INC
$3.65B$31.02M-$71.35M-$90.10M-$0.93N/A42.89%N/AN/A2024-03-14
DOMH
DOMINARI HOLDINGS INC
$11.23M$1.03M-$23.11M-$23.22M-$4.48N/A29.49%N/AN/A2024-03-29
PBYI
PUMA BIOTECHNOLOGY INC
$311.59M$229.13M$28.65M$3.72M$0.075.25%2.60%-68.18%N/A2024-02-29
AUTL
AUTOLUS THERAPEUTICS PLC
$1.06B$5.52M-$150.82M-$158.16M-$0.98103.43%31.45%N/AN/A2024-03-05
GNFT
GENFIT SA
$182.40M$31.65M-$28.45M-$36.36M-$0.73-67.08%N/AN/AN/A2024-04-04
MDWD
MEDIWOUND LTD
$123.54M$24.97M-$1.77M-$12.43M-$1.8522.59%53.40%N/AN/A2024-03-14
RNAC
CARTESIAN THERAPEUTICS INC
$113.30M$34.53M-$30.31M-$36.16M-$0.24-72.13%358.73%N/AN/A2024-02-29
ADMA
ADMA BIOLOGICS INC
$1.19B$234.29M$9.88M-$22.83M-$0.1179.56%56.53%N/AN/A2024-03-21
CRBU
CARIBOU BIOSCIENCES INC
$613.71M$34.61M-$89.25M-$94.55M-$1.51172.14%N/AN/AN/A2024-03-18
ARDX
ARDELYX INC
$2.02B$124.46M-$55.65M-$66.07M-$0.30138.61%116.66%N/AN/A
CGEN
COMPUGEN LTD
$206.47M$7.50M-$32.95M-$33.46M-$0.3925.00%-5.59%N/AN/A2024-03-05
MTNB
MATINAS BIOPHARMA HOLDINGS INC
$51.93M$4.28M-$20.34M-$21.26M-$0.1198.43%N/AN/AN/A2024-03-13
SILO
SILO PHARMA INC
$4.88M$72.10k-$4.23M-$4.24M-$1.400.00%N/AN/AN/A2024-02-28
TGTX
TG THERAPEUTICS INC
$2.02B$189.77M-$12.61M-$25.91M-$0.203,676.56%316.18%N/AN/A2024-02-28
BGNE
BEIGENE LTD
$16.24B$2.20B-$900.11M-$959.49M-$0.7176.38%69.47%N/AN/A2024-02-26
ALLO
ALLOGENE THERAPEUTICS INC
$763.98M$186.00k-$319.07M-$332.86M-$2.23-24.70%N/AN/AN/A2024-02-26
RYTM
RHYTHM PHARMACEUTICALS INC
$2.67B$61.98M-$170.86M-$185.54M-$3.24271.94%N/AN/AN/A
SAGE
SAGE THERAPEUTICS INC
$1.32B$86.46M-$540.10M-$541.49M-$9.051,024.84%-0.86%N/AN/A
KRYS
KRYSTAL BIOTECH INC
$3.14B$8.56M-$26.15M-$29.81M-$1.38N/AN/AN/AN/A2024-02-26
ZVRA
ZEVRA THERAPEUTICS INC
$240.13M$16.56M-$38.67M-$39.92M-$1.1554.49%N/AN/AN/A2024-03-05
ENTX
ENTERA BIO LTD
$30.25M$14.00k-$9.89M-$9.93M-$0.34-95.09%N/AN/AN/A2024-03-29
LUMO
LUMOS PHARMA INC
$23.74M$1.74M-$32.81M-$32.82M-$4.0041.10%-40.02%N/AN/A2024-02-28
PRTC
PURETECH HEALTH PLC
$746.84M$15.62M-$97.18M-$50.35M-$1.80-10.18%43.86%N/AN/A
STOK
STOKE THERAPEUTICS INC
$265.24M$9.25M-$107.53M-$103.40M-$2.421.21%N/AN/AN/A2024-03-04
CDTX
CIDARA THERAPEUTICS INC
$63.30M$56.54M-$30.03M-$31.37M-$0.39-7.75%N/AN/AN/A2024-03-21
MRUS
MERUS NV
$2.74B$45.67M-$175.41M-$176.76M-$3.760.10%7.41%N/AN/A2024-02-26
BCYC
BICYCLE THERAPEUTICS PLC
$1.05B$26.98M-$169.40M-$180.66M-$5.0886.52%30.47%N/AN/A
CMRX
CHIMERIX INC
$104.89M$1.13M-$85.00M-$84.89M-$0.96-96.57%-23.02%N/AN/A2024-02-29

Biotech Stocks FAQ

What are the best biotech stocks to buy right now in Feb 2024?

According to Zen Score, the 3 best biotechnology stocks to buy right now are:

1. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the top biotech stock with a Zen Score of 75, which is 53 points higher than the biotech industry average of 22. It passed 24 out of 33 due diligence checks and has strong fundamentals. Incyte has seen its stock lose -21.98% over the past year, overperforming other biotech stocks by 2 percentage points.

Incyte has an average 1 year price target of $74.55, an upside of 23.03% from Incyte's current stock price of $60.59.

Incyte stock has a consensus Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Incyte, 27.27% have issued a Strong Buy rating, 18.18% have issued a Buy, 54.55% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Harmony Biosciences Holdings (NASDAQ:HRMY)


Harmony Biosciences Holdings (NASDAQ:HRMY) is the second best biotech stock with a Zen Score of 70, which is 48 points higher than the biotech industry average of 22. It passed 23 out of 33 due diligence checks and has strong fundamentals. Harmony Biosciences Holdings has seen its stock lose -29.5% over the past year, underperforming other biotech stocks by -6 percentage points.

Harmony Biosciences Holdings has an average 1 year price target of $40.88, an upside of 25.77% from Harmony Biosciences Holdings's current stock price of $32.50.

Harmony Biosciences Holdings stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Harmony Biosciences Holdings, 50% have issued a Strong Buy rating, 25% have issued a Buy, 0% have issued a hold, while 12.5% have issued a Sell rating, and 12.5% have issued a Strong Sell.

3. Arcturus Therapeutics Holdings (NASDAQ:ARCT)


Arcturus Therapeutics Holdings (NASDAQ:ARCT) is the third best biotech stock with a Zen Score of 70, which is 48 points higher than the biotech industry average of 22. It passed 23 out of 33 due diligence checks and has strong fundamentals. Arcturus Therapeutics Holdings has seen its stock return 115.8% over the past year, overperforming other biotech stocks by 139 percentage points.

Arcturus Therapeutics Holdings has an average 1 year price target of $49.50, an upside of 32.28% from Arcturus Therapeutics Holdings's current stock price of $37.42.

Arcturus Therapeutics Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Arcturus Therapeutics Holdings, 50% have issued a Strong Buy rating, 50% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the biotech stocks with highest dividends?

Out of 6 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

1. Gyre Therapeutics (NASDAQ:GYRE)


Gyre Therapeutics (NASDAQ:GYRE) has an annual dividend yield of N/A, which is N/A percentage points lower than the biotech industry average of 11.62%. Gyre Therapeutics's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Gyre Therapeutics's dividend has not shown consistent growth over the last 10 years.

Gyre Therapeutics's dividend payout ratio of -17.4% indicates that its dividend yield might not be sustainable for the long-term.

2. Mei Pharma (NASDAQ:MEIP)


Mei Pharma (NASDAQ:MEIP) has an annual dividend yield of 40.6%, which is 29 percentage points higher than the biotech industry average of 11.62%.

Mei Pharma's dividend payout ratio of 58.9% indicates that its high dividend yield is sustainable for the long-term.

3. Carisma Therapeutics (NASDAQ:CARM)


Carisma Therapeutics (NASDAQ:CARM) has an annual dividend yield of 14.94%, which is 3 percentage points higher than the biotech industry average of 11.62%.

Carisma Therapeutics's dividend payout ratio of -9.6% indicates that its high dividend yield might not be sustainable for the long-term.

Why are biotech stocks up?

Biotech stocks were up 0.89% in the last day, and up 0.62% over the last week. Maravai Lifesciences Holdings was the among the top gainers in the biotechnology industry, gaining 63.6% yesterday.

Maravai LifeSciences shares are trading higher after the company reported better-than-expected Q4 financial results.

What are the most undervalued biotech stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued biotech stocks right now are:

1. Revelation Biosciences (NASDAQ:REVB)


Revelation Biosciences (NASDAQ:REVB) is the most undervalued biotech stock based on WallStreetZen's Valuation Score. Revelation Biosciences has a valuation score of 100, which is 84 points higher than the biotech industry average of 16. It passed 7 out of 7 valuation due diligence checks.

Revelation Biosciences's stock has dropped -95.78% in the past year. It has underperformed other stocks in the biotech industry by -72 percentage points.

2. Voyager Therapeutics (NASDAQ:VYGR)


Voyager Therapeutics (NASDAQ:VYGR) is the second most undervalued biotech stock based on WallStreetZen's Valuation Score. Voyager Therapeutics has a valuation score of 100, which is 84 points higher than the biotech industry average of 16. It passed 7 out of 7 valuation due diligence checks.

Voyager Therapeutics's stock has gained 18.21% in the past year. It has overperformed other stocks in the biotech industry by 42 percentage points.

3. Incyte (NASDAQ:INCY)


Incyte (NASDAQ:INCY) is the third most undervalued biotech stock based on WallStreetZen's Valuation Score. Incyte has a valuation score of 86, which is 70 points higher than the biotech industry average of 16. It passed 6 out of 7 valuation due diligence checks.

Incyte's stock has dropped -21.98% in the past year. It has overperformed other stocks in the biotech industry by 2 percentage points.

Are biotech stocks a good buy now?

47.46% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 64.63% over the next year.

What is the average p/e ratio of the biotechnology industry?

The average P/E ratio of the biotechnology industry is 16.16x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.